XML 45 R35.htm IDEA: XBRL DOCUMENT
v3.23.3

REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 7,051 | $ 7,042 | $ 20,002 | $ 19,892
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5,017 | 4,928 | 14,253 | 13,622
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,040 | 1,101 | 3,146 | 3,378
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 993 | 1,013 | 2,603 | 2,891
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6,994 | 6,978 | 19,864 | 19,650
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,985 | 4,900 | 14,196 | 13,482
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,017 | 1,064 | 3,069 | 3,281
Total product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 992 | 1,013 | 2,599 | 2,887
Total HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,667 | 4,487 | 13,482 | 12,422
Total HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,807 | 3,661 | 10,949 | 9,906
Total HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 519 | 541 | 1,568 | 1,653
Total HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 341 | 285 | 965 | 863
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,085 | 2,766 | 8,741 | 7,472
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,504 | 2,286 | 7,104 | 6,088
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 313 | 278 | 920 | 807
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 268 | 201 | 717 | 577
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 43 | 104 | 142
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 20 | 40 | 56
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 18 | 21 | 55 | 76
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 9 | 10
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 511 | 500 | 1,475 | 1,335
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 460 | 444 | 1,314 | 1,152
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 28 | 75 | 92
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 28 | 86 | 91
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 503 | 600 | 1,544 | 1,764
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 433 | 502 | 1,305 | 1,441
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 47 | 71 | 157 | 220
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 23 | 27 | 81 | 103
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 343 | 374 | 1,011 | 1,077
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 257 | 276 | 754 | 763
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 74 | 86 | 223 | 278
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 11 | 12 | 33 | 36
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 32 | 79 | 98
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 18 | 22 | 57 | 68
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 7 | 16 | 23
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 3 | 6 | 7
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 22 | 30 | 97 | 102
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 24 | 71 | 77
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 10 | 12
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 2 | 16 | 13
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 131 | 130 | 390 | 388
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 96 | 85 | 278 | 251
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 32 | 40 | 101 | 126
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 4 | 10 | 10
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 12 | 41 | 45
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 10 | 1 | 24 | 11
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 6 | 11 | 20
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 5 | 6 | 15
Total Oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 769 | 578 | 2,167 | 1,525
Total Oncology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 462 | 409 | 1,354 | 1,067
Total Oncology | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 243 | 149 | 660 | 407
Total Oncology | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 65 | 20 | 153 | 52
Total Cell Therapy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 486 | 398 | 1,402 | 1,040
Total Cell Therapy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 261 | 270 | 802 | 688
Total Cell Therapy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 181 | 111 | 491 | 308
Total Cell Therapy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 45 | 17 | 109 | 44
Tecartus |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 96 | 81 | 272 | 217
Tecartus | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 64 | 60 | 179 | 160
Tecartus | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 27 | 20 | 83 | 56
Tecartus | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 1 | 11 | 2
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 391 | 317 | 1,130 | 823
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 197 | 210 | 624 | 528
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 154 | 91 | 408 | 253
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 40 | 16 | 99 | 42
Trodelvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 283 | 180 | 764 | 485
Trodelvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 201 | 139 | 551 | 379
Trodelvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 62 | 38 | 169 | 98
Trodelvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 21 | 3 | 44 | 8
Total Liver Disease |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 706 | 788 | 2,093 | 2,104
Total Liver Disease | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 376 | 413 | 1,051 | 1,056
Total Liver Disease | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 119 | 170 | 390 | 417
Total Liver Disease | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 211 | 204 | 652 | 631
Total HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 438 | 524 | 1,335 | 1,371
Total HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 260 | 283 | 751 | 745
Total HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 85 | 143 | 294 | 332
Total HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 93 | 98 | 289 | 294
Ledipasvir/Sofosbuvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 23 | 25 | 54 | 83
Ledipasvir/Sofosbuvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 8 | 29 | 27
Ledipasvir/Sofosbuvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 5 | 11 | 13
Ledipasvir/Sofosbuvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 12 | 14 | 43
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 377 | 455 | 1,159 | 1,161
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 215 | 241 | 643 | 629
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 76 | 131 | 250 | 288
Sofosbuvir/Velpatasvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 85 | 84 | 266 | 244
Other HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 38 | 44 | 123 | 127
Other HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 34 | 80 | 88
Other HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 7 | 33 | 31
Other HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 2 | 10 | 7
Total HBV/HDV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 269 | 264 | 758 | 733
Total HBV/HDV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 116 | 131 | 299 | 311
Total HBV/HDV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 28 | 96 | 85
Total HBV/HDV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 119 | 106 | 363 | 337
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 228 | 228 | 645 | 622
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 112 | 129 | 295 | 306
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 9 | 28 | 27
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 106 | 90 | 322 | 289
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 21 | 22 | 62 | 69
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 2 | 4 | 4
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 5 | 17 | 17
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 15 | 40 | 48
Other HBV/HBD |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 20 | 14 | 51 | 42
Other HBV/HBD | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 1
Other HBV/HBD | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 19 | 13 | 50 | 41
Other HBV/HBD | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Veklury |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 636 | 925 | 1,465 | 2,905
Veklury | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 258 | 336 | 607 | 1,179
Veklury | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 65 | 130 | 227 | 560
Veklury | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 313 | 458 | 630 | 1,166
Total Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 216 | 200 | 658 | 693
Total Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 82 | 80 | 236 | 275
Total Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 72 | 75 | 224 | 244
Total Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 62 | 46 | 199 | 174
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 115 | 105 | 381 | 380
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 9 | 39 | 48
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 63 | 63 | 192 | 192
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 39 | 33 | 150 | 140
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 36 | 43 | 106 | 135
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 36 | 43 | 106 | 135
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 65 | 52 | 171 | 178
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 28 | 91 | 91
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 11 | 31 | 52
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 23 | 13 | 49 | 35
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 56 | 64 | 138 | 242
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 32 | 28 | 57 | 140
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 23 | 37 | 77 | 98
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 1 | $ 0 | $ 4 | $ 4

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |